Synergistic Targeting of the MAP Kinase Pathway in Melanoma

$425,498P01FY2013CANIH

Wistar Institute, Philadelphia PA

Investigators

Linked publications & trials

Paper 39700408 Paper 39579354 Paper 39311587 Paper 39265628 Paper 39255061 Paper 39248505 Paper 39243764 Paper 39007351 Paper 38766222 Paper 38472454 Paper 38330147 Paper 38263597 Paper 37932277 Paper 37847239 Paper 37723305 Paper 37639774 Paper 37468627 Paper 37444561 Paper 37343247 Paper 37229906 Paper 37059066 Paper 36931971 Paper 36916687 Paper 36795483 Paper 36633146 Paper 36331284 Paper 36280724 Paper 36220073 Paper 36054930 Paper 36052501 Paper 35731974 Paper 35657206 Paper 35650633 Paper 35650435 Paper 35650266 Paper 35554228 Paper 35513054 Paper 35508111 Paper 35426938 Paper 35420772 Paper 35296667 Paper 35144882 Paper 35071745 Paper 35046531 Paper 35041192 Paper 34937742 Paper 34883044 Paper 34862480 Paper 34830283 Paper 34801549 Paper 34766134 Paper 34737210 Paper 34654806 Paper 34518212 Paper 34462276 Paper 34304249 Paper 34298133 Paper 34127435 Paper 34085048 Paper 34011536 Paper 33979613 Paper 33941922 Paper 33860080 Paper 33767420 Paper 33741967 Paper 33720046 Paper 33568355 Paper 33545064 Paper 33452215 Paper 33451983 Paper 33446574 Paper 33436641 Paper 33414553 Paper 33414169 Paper 33414132 Paper 33398196 Paper 33262126 Paper 33208912 Paper 33170774 Paper 33097493 Paper 33055209 Paper 33023943 Paper 32780726 Paper 32733068 Paper 32661093 Paper 32641416 Paper 32584791 Paper 32499221 Paper 32396847 Paper 32274887 Paper 32032511 Paper 31980749 Paper 31980600 Paper 31942031 Paper 31838023 Paper 31836838 Paper 31836388 Paper 31714594 Paper 31696640 Paper 31519915

Abstract

The overall goal of project 4 is to develop novel approaches distinct from ATP mimetics to overcome resistance to BRAF inhibitors for treatment of melanoma. This project will focus on two mechanisms of resistance; BRAF dimerization leading to paradoxical MAPK activation and STATS activation which is downstream of a number of parallel signaling pathways that are activated in BRAF inhibitor resistant cells as well as in BRAF^'

View original record on NIH RePORTER →